NEU 1.15% $20.72 neuren pharmaceuticals limited

ANAVEX MEETS ENDPOINTS PHASE2 RETT, page-159

  1. 5,983 Posts.
    lightbulb Created with Sketch. 1548
    IMO, this represents a 'potential' glaring error in the wording of the contract, because if push came to shove, Acadia would very likely succeed in any litigation, simply due to a literal reading of the contract wording.

    I say 'potential', because (once again IMO) it is quite unlikely that the two companies would engage in a dog fight, when there is a high probability that any TO of Neuren would involve a simultaneous or subsequent TO of Acadia, by the acquiring company, giving it total ownership of the original Neuren technology.

    So perhaps the loose contract wording may have been overlooked due to recognition of the likelihood of the above scenario playing out.

    [Lots of holes there I guess, but at least it puts MY mind at rest.]
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.72
Change
-0.240(1.15%)
Mkt cap ! $2.645B
Open High Low Value Volume
$21.00 $21.21 $20.31 $15.80M 766.0K

Buyers (Bids)

No. Vol. Price($)
1 2000 $20.70
 

Sellers (Offers)

Price($) Vol. No.
$20.72 3108 1
View Market Depth
Last trade - 16.10pm 30/05/2024 (20 minute delay) ?
Last
$20.75
  Change
-0.240 ( 1.47 %)
Open High Low Volume
$20.97 $21.15 $20.32 199599
Last updated 15.59pm 30/05/2024 ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.